Takeo Arita

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

T. Koga, Kenichi Suda, Toshio Fujino et al. · Journal of Thoracic Oncology · 2021 · 231 citations · Full text

Vitro Experiments, Kras Secondary Mutations, Novel Therapy +9

Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma

Akito Nakamura, Takeo Arita, Shuntarou Tsuchiya et al. · Cancer Research · 2013 · 122 citations

Antitumor Activity, Raf Dimer, Tumor Biology +16

Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of <i>C</i>-7-Substituted 1,3-Benzothiazole Derivatives

Masanori Okaniwa, Masaaki Hirose, Takeo Arita et al. · Journal of Medicinal Chemistry · 2013 · 111 citations · Full text

Design and Synthesis of Novel DFG-Out RAF/Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitors. 1. Exploration of [5,6]-Fused Bicyclic Scaffolds

Masanori Okaniwa, Masaaki Hirose, Takashi Imada et al. · Journal of Medicinal Chemistry · 2012 · 76 citations

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

Kohei Shitara, Yung‐Jue Bang, Satoru Iwasa et al. · Nature Medicine · 2024 · 74 citations · Full text